CMS is a heterogeneous disease that impairs NMT [1, 2]. The clinical features of CMS are motor disorders, weakness, and muscle atrophy. There are several differences between CMS and autoimmune myasthenia gravis (MG). First, autoimmune MG is an acquired disease caused by autoantibodies against the acetylcholine receptors. In contrast, CMSs are congenital diseases and are caused by various deficiencies of presynaptic-, synaptic interval-, and postsynaptic elements. Second, because of their differences, CMSs require different therapeutic strategies than those used for autoimmune MG.

Many genetic mutations are associated with CMS, which influence its clinical features, severity, and response to treatment. Of the 25 mutations known to cause CMS, most show an autosomal recessive form of inheritance. The most common cause of CMS is a defect in the synaptic interval, especially in the acetylcholine receptor. Mutation in the COLQ gene causes a defect in collagen Q that anchors acetylcholinesterase to the basal lamina, resulting in an extended residence of acetylcholine in the synaptic interval, leading to excessive acetylcholine receptor activation. Ephedrine is effective for treating the clinical symptoms of CMS with COLQ gene mutation, but acetylcholinesterase inhibitors aggravate the phenotype of CMS.

Few reports have described the use of general anesthesia to manage CMS. Emura et al. [3] did not use neuromuscular blockers and continued mechanical ventilation until the day after the operation for scoliosis in patients with CMS. They reported abdominal bloating after NPPV administration in that patient and considered that it was caused by air injection from NPPV because of decreasing lung-thoracic compliance. A few researchers have reported that regional anesthesia can safely be performed in patients with CMS [4]. According to a review by Gilmore, these patients can be managed using experience with treating autoimmune myasthenia gravis [2].

For the anesthetic management of patients with CMS, knowing the CMS phenotype and treatment is necessary. For example, acetylcholinesterase inhibitors can worsen some CMS phenotypes, while improving others. Volatile anesthetic agents reportedly decrease the neuromuscular function in autoimmune myasthenia gravis. McBeth et al. reported the use of isoflurane for sedating a patient with CMS, concluding that using 1–2.5% isoflurane is a safe and easy method of sedation that avoids the use of a neuromuscular blocking agent [5]. The safety of propofol and midazolam is unclear, but we presumed that they can safely be used in patients with CMS, similar to their use in treating autoimmune myasthenia gravis. Succinylcholine is expected to worsen the existing state of excitotoxicity in some CMS phenotypes and should be avoided in patients with CMS. CMS patients have an exaggerated response to nondepolarizing neuromuscular blockers, but an acetylcholinesterase inhibitor used as a medication for some phenotypes of CMS may decrease the response to such blockers. Therefore, nondepolarizing neuromuscular blockers should be titrated with NMT monitoring.

Postoperative respiratory management of patients with CMS is difficult. NPPV may be beneficial against respiratory dysfunction and the effect of residual anesthetic agents. We extubated in the operating room in this case because the pediatric intensive care unit of our institution is used for respiratory management and NPPV. Nevertheless, invasive positive pressure ventilation in the early postoperative period should be considered for each patient and institution.

Postoperative analgesia is very important for patients after scoliosis surgery. However, patients with CMS have compromised respiratory functions, and using opioids in them may pose a greater risk of adverse events. Choi et al. reported that administering opioids (fentanyl or oxycodone) reduces airway reflex at tracheal extubation in patients undergoing cholecystectomy but reported no postoperative respiratory complications [6]. Moreover, a continuous infusion of fentanyl may increase the risks of weakness of airway reflex and respiratory depression. Therefore, reducing opioids by introducing multimodal analgesia (using opioids with non-steroidal anti-inflammatory drugs, acetaminophen, and regional analgesia) should be considered in patients with CMS, which has also been an important consideration in patients with MG [7]. Additionally, rigorous monitoring in the ICU is needed until the patients fully recover to reach their preoperative respiratory conditions.

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit


This article is autogenerated using RSS feeds and has not been created or edited by OA JF.

Click here for Source link (